65,437 trials
Alzheimer's Disease
Primary: Change From Baseline Over Time in CDR-SB Score — 0.60; 0.66; 0.44; 0.63 score on a scale — p=0.740
Cholestasis of Parenteral Nutrition
Primary: Number of Participants With Cholestasis — 1; 3; 7 Participants — p=0.590
Congenital Ichthyosis
Primary: Number of Subjects With Reduction in Targeted Ichthyosis Severity Using the Visual Index for Ichthyosis Severity Measurement — 4; 7; 4 Participants
Granulomatosis With Polyangiitis (GPA) · Microscopic Polyangiitis (MPA)
Primary: Percentage of Subjects Achieving Clinical Response — 16; 22; 10 Participants
Breast Tumor
Primary: Number of Participants With Successful Localization — 9; 15; 12 Participants
Myasthenia Gravis · Myasthenia Gravis, Juvenile Form · Myasthenia Gravis, Generalized
Primary: Change From Baseline in the QMG Total Score at Week 26 Regardless of Rescue Treatment — -6.1 units on a scale — p=0.0004
Heart Diseases
Primary: Hospitalizations — 0.98; 1.48 hospitalizations
Head and Neck Cancer · Human Papilloma Virus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 15; 9; 11; 4 Participants
Gastric Cardia Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Stage IB Gastric Cancer AJCC v7
Primary: Pathological Complete Response (PathCR) Rate — 22.6 percentage of patients
Multiple Sclerosis
Primary: Neuropathic Pain Questionnaire (NPQ) Contains 12 Items. — 21.3; 10.3 Points
Type 1 Diabetes Mellitus
Primary: Time in Target Range — 67.6; 60.4; 69 percentage of time in range — p=<0.001
AIDS · HIV
Primary: Change From Vaccination (Day 0) in Mean CD4+ T Cell-associated HIV RNA Transcription at Day 7 — -471.8; -45.9; 332.3 HIV RNA copies per million cell — p=0.32
Atrial Fibrillation
Primary: SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF] — NA; NA; NA; 88.6 percentage of participants
Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Emergent Treatment Related AEs and…
Asthma
Primary: Area Under the Serial Forced Expiratory Volume in 1 Second (FEV1) — 4.4453; 4.2790; 1.6876 l * hr